Equillium   Report issue

For profit Phase 2 Phase 3
Founded: La Jolla CA United States (2017)

Organization Overview

First Clinical Trial
2019
NCT04007198
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Equillium | Equillium, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

itolizumab (5 trials)

Drugs in Phase 2 Trials (6)

Key: Equillium (1) Acquired (5)

bnz-1 (1 trial)

bnz132-1-40 (3 trials)

cilofexor (1 trial)

empagliflozin (jardiance) (1 trial)

eq101 (1 trial)

met642 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 1)

Coronavirus Infections (Phase 3)

Graft vs Host Disease (Phase 2)

Lupus Erythematosus, Systemic (Phase 1)

Lupus Nephritis (Phase 1)

Nephritis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 7